TransplantationOct 27, 2026

Effects of Glucagon-like Peptide-1 Drugs in Heart Transplant Patients with Type 2 Diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 28, 2026

Abstract

Type 2 diabetes mellitus (T2DM) is frequent after heart transplantation, and immunosuppressive therapy may worsen this condition.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could potentially enhance metabolic control in heart transplant recipients.
Current data on the effectiveness of GLP-1 RAs in this specific population is limited.
T2DM is a common complication following heart transplantation.

Simplified

Full Text

Full text is available at the source.

View Full Text ↗

Weekly GLP-1 Therapies Brief

You found one interesting study. We’ll send the next 7.

Get 7 new glp-1 therapies papers each week, explained in plain English with direct links to the originals.

What Lands in Your Inbox Each Week:

📚7 fresh studies
📝plain-language summaries
✅direct links to original studies
🏅top journal indicators
📅weekly delivery
🧘‍♂️always free

Recent issues from the glp-1 therapies brief

GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes

2 weeks ago7 studies

A new triple receptor drug cut body weight by nearly 20% in 24 weeks

3 weeks ago7 studies

A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial

4 weeks ago7 studies

Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it

5 weeks ago7 studies

The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated

6 weeks ago7 studies

GLP-1 drugs don't build habits — and that gap is costing patients their results

7 weeks ago7 studies

Semaglutide slowed aging and extended lifespan in older female mice

8 weeks ago7 studies

GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes

9 weeks ago7 studies

Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes

10 weeks ago7 studies

A once-daily pill beat placebo on weight loss — and it wasn't semaglutide

11 weeks ago7 studies

explore the archive

See more issues from the glp-1 therapies brief